Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® subject to certain conditions, Advancing the Global Development and Commercialization of a Non-Surgical Treatment for Cervical Precancerous Lesions in Europe

PartnershipCEVIRA®Positive

AI Analysis

Summary

Asieris Pharmaceuticals has entered an exclusive licensing agreement with Theramex for CEVIRA®, granting Theramex rights in Europe, Australia, New Zealand, and Turkey. The agreement includes $15 million upfront payment and $11 million in near-term regulatory milestones.

Outcome Details

Exclusive licensing agreement subject to certain conditions

Importance:7/10

Sentiment:

0.65

licensing agreementexclusive rightsEuropecervical cancer preventioncommercial partnership

Related Companies

$ZEAL $GBCMD $WHEN

Read the original article

Published by PR Newswire Biotech on October 7, 2026 1:35 PM

Read Original